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Contrary to current models, Scherrer et al. (2009) provide evidence that mu and delta opioid recep-
tors are not expressed by the same pain-sensing neurons. In mice, agonists for these receptors 
produce analgesia restricted to either noxious heat or mechanical stimuli, implying that the recep-
tors act on distinct fibers to mediate completely different types of pain relief.It is relatively rare in neurobiology that a 
discovery forces a sudden re-evaluation 
of an established dogma. The paper by 
Scherrer et al. (2009) in this issue chal-
lenges the prevailing view concerning 
opioid receptors and the analgesia they 
produce. The current models are predi-
cated on interactions in primary sensory 
neurons between two different types of 
opioid receptors (mu and delta) and with 
the neuropeptide substance P. Scherrer 
et al. provide evidence that these inter-
actions are unlikely to occur for a very 
simple reason—the key players do not 
appear to be coexpressed in the same 
neuron.
Morphine was isolated from opium in 
1805 by Sertürner, who named the com-
pound after the Greek god of dreams 
because of the state of altered con-
sciousness it produced. While “in the 
arms of Morpheus” there is also pro-
found analgesia, making morphine the 
gold standard for pain relief. The 1973 
discovery of opioid-binding proteins 
by Pert and Snyder provoked a race 
to identify the receptors, which were 
differentiated pharmacologically into 
distinct subtypes by Martin. The delta 
opioid receptor (DOR) was the first to 
be cloned independently by Kieffer and 
Evans in 1992, soon followed by the mu 
opioid receptor (MOR). These are both 
inhibitory G protein-coupled recep-
tors (GPCRs), as is the kappa opioid 
receptor (KOR). Once it was shown that 
knocking out the MOR gene completely 
eliminates the analgesic action of mor-
phine, the pivotal role of this receptor 
in pain biology was firmly cemented 
(Matthes et al., 1996). The role of DOR 
remained more complex; neverthe-
less, there is reduction in some anal-gesic signals in mice lacking DOR and, 
perhaps more surprisingly, decreased 
analgesic tolerance to morphine, hint-
ing at possible interaction between the 
MOR and DOR (Zhu et al., 1999).
Because activation of MOR produces 
not only analgesia but also respiratory 
depression, sedation, nausea, and con-
stipation, as well as euphoria, there has 
been an active search for opiates with 
the analgesic efficacy of MOR agonists 
but without their side effects, depen-
dence, tolerance, and abuse liability—so 
far with no clinical success. KOR ago-
nists produce intense dysphoria and 
diuresis, and some DOR agonists induce 
seizures, both showstoppers. However, 
the insights generated by Scherrer et al. 
make it time to reopen the DOR as an 
analgesic target.
MOR is expressed by a subset of 
nociceptor (noxious stimulus detecting) 
sensory neurons that express the neu-
ropeptide substance P and the noxious 
heat transducer TRPV1. MOR on presyn-
aptic axon terminals in the spinal cord 
reduces transmitter release by inhibiting 
voltage-gated calcium channels, dimin-
ishing sensory input from nociceptors 
to the central nervous system (CNS). 
The receptor is also located postsynati-
cally, where it activates GIRK potassium 
channels to reduce excitability. MOR is 
widely expressed in the CNS. However, 
it is likely that the spinal cord is a major 
contributor to analgesia because intrath-
ecal administration of MOR agonists 
produces analgesia, and that of MOR 
antagonists reduces analgesia produced 
by systemic opiates.
DOR too is expressed in primary 
sensory neurons (and in many CNS 
neurons) and, until the study of Scher-Cell rer et al., was thought to be coex-
pressed in exactly the same peptider-
gic nociceptor neurons as MOR. This 
combined with data from heterologous 
expression systems showing that the 
receptors form heterodimers and the 
finding that DOR antagonism leads 
to a reduction in morphine tolerance 
led to the suggestion that MOR-DOR 
complexes are an important contribu-
tor to the development of tolerance 
to MOR agonists (Decaillot et al., 
2008; Gomes et al., 2004). Although 
the study of Scherrer et al. does not 
exclude such MOR-DOR interactions 
in CNS neurons, it suggests minimal 
opportunity for heterodimer formation 
in  nociceptors.
DOR is also proposed to interact via 
an extracellular loop with substance P 
to mediate its trafficking to the mem-
brane of nocicepter central terminals in 
the spinal cord (Guan et al., 2005). This 
model is important because immuno-
histochemical studies report that DOR 
is absent from the presynaptic mem-
brane under control conditions, which 
implies no activity in response to DOR 
agonists in the resting state. Instead, 
DOR is supposed to be stored in the 
membrane of large dense core vesicles 
(LDCVs) that contain substance P and 
becomes incorporated into the plasma 
membrane only on exocytosis of the 
vesicles (Bao et al., 2003; Gendron et 
al., 2006; Guan et al., 2005). Hence, acti-
vation of nociceptors would promote a 
cumulative increase in responsiveness 
to DOR agonists, implying efficacy only 
in those pathological circumstances 
with ongoing sensory input and release 
of substance P (Gendron et al., 2006; 
Guan et al., 2005). Alas this model 137, June 12, 2009 ©2009 Elsevier Inc. 987
looks as if it may have to be abandoned 
because Scherrer et al. show that DOR 
is not expressed in substance P-con-
taining neurons. In addition, it looks 
like it behaves as a prototypic GPCR 
with membrane expression in basal 
conditions and internalization on acti-
vation, rather than the use-dependent 
insertion into the membrane suggested 
in current models.
What has so muddied the waters? It 
turns out that perhaps all commercially 
available antibodies raised against 
DOR peptides recognize a protein that 
is still present in mice lacking DOR 
and all immunohistochemistry using 
these antibodies is therefore suspect. 
Scherrer et al. use a DOR-enhanced 
green fluorescent protein (EGFP) 
reporter mouse to show that the recep-
tor is localized in the set of presump-
tive nociceptor neurons that do not 
express substance P. The often made 
jest that the most valuable contribution 
of knockouts is to test antibody speci-
ficity is not a joke. What protein these 
antibodies recognize and its involve-
ment in opioid receptor biology are 
now open questions, as is how sub-
stance P may contribute to morphine 
tolerance. DOR reporters with Myc and 988 Cell 137, June 12, 2009 ©2009 Elsevier 
The vascular system comprises an elabo-
rate network of arteries, capillaries, and 
veins that penetrate all body tissues to 
provide oxygen and nutrients and to 
remove waste. During development, 
new blood vessels form by sprouting 
into avascular zones in a process known 
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Sprouting blood vessels have 
(2009) now show that competiti
glycosylation of Notch recepto
and Delta-like 4.hemagluttinin tags are expressed in 
LDCVs whereas those with a smaller 
GFP tag are located on the cell surface 
and interact with agonists (Wang et al., 
2008), a further source of potential arti-
fact.
Scherrer et al. argue that expression 
of MOR in TRPV1-expressing nocicep-
tor neurons contributes to analgesia for 
heat pain whereas DOR action in non-
peptidergic sensory neurons results 
in reduction only in mechanical pain. 
These results are intriguing, suggest-
ing that although most nociceptors are 
activated by both heat and mechanical 
stimuli, the input somehow and unex-
pectedly enters the CNS via anatomi-
cally distinct channels. This appears 
difficult to reconcile though with the 
very substantial clinical experience that 
morphine’s analgesic actions are not 
limited to heat pain and the observa-
tion that DOR agonists can very effec-
tively reduce heat pain after peripheral 
inflammation (Codd et al., 2009). Many 
exciting questions remain, not least 
whether DOR agonists will join MOR 
agonists in the pantheon of clinically 
useful opiate analgesics if their pro-
pensity to induce seizures can be fully 
overcome.Inc.
as angiogenesis. The primary driver of 
angiogenesis is hypoxia (lack of oxygen). 
Hypoxia accompanies tissue growth and 
triggers the release of angiogenic growth 
factors, the best studied of which is vas-
cular endothelial growth factor (VEGF). 
Endothelial cells line blood vessels and 
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response to VEGF, they become activated 
and promote the sprouting of new ves-
sels. The tips of these sprouts are formed 
by specialized endothelial cells called tip 
cells (Figure 1). Tip cells are migratory and 
extend numerous filopodia to sense their 
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 of the Notch ligands Jagged1 
